更新于：2024-12-14
Cefuroxime Sodium
头孢呋辛钠
更新于：2024-12-14
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H16N4NaO8S |
InChIKeyBAJSKIYRJKPEIM-JTBFTWTJSA-N |
CAS号56238-63-2 |
关联
66
项与 头孢呋辛钠 相关的临床试验Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.
Efficacy and safety of quadruple therapy containing tigolaxant and cefuroxime in the treatment of Helicobacter pylori infection in patients with penicillin allergy
100 项与 头孢呋辛钠 相关的临床结果
登录后查看更多信息
100 项与 头孢呋辛钠 相关的转化医学
登录后查看更多信息
100 项与 头孢呋辛钠 相关的专利（医药）
登录后查看更多信息
4,779
项与 头孢呋辛钠 相关的文献（医药）2025-02-01Infectious disorders drug targets
A Case Report of Salmonella enterica Meningitis in an Infant: A Rare Entity not to Forget
Article
作者: Tzanoudaki, Marianna ; Farmaki, Evangelia ; Gkentzi, Despoina ; Syrogiannopoulos, George ; Palyvou, Maria ; Angeli, Evangelia ; Varvarigou, Anastasia ; Dimitriou, Gabriel
Introduction::
Salmonellae are gram-negative, facultatively anaerobic Enterobacteri-aceae consisting of two species, Salmonella enterica and Salmonella bongori. Invasive diseases, such as meningitis, result in hospitalization, short and long-term complications, and high mortality rates.
Case Presentation::
A 4-month-old baby girl was admitted to a district hospital because of diarrhea and fever. WBC count, urinalysis, urine cultures, and stool cultures were normal. She was treated with intravenous cefuroxime for 5 days. She was discharged on oral cefprozil for 5 days. After the end of therapy, she was admitted again to the same hospital with fever, diarrhea, vomits, and irri-tability. Cerebrospinal fluid examination revealed pleocytosis, while S. enterica was isolated. Em-pirical therapy with ceftriaxone, amikacin, and dexamethasone was started. Because of intracranial hypertension signs, she was transferred to the pediatric intensive care unit of our tertiary hospital. Therapy continued with intravenous ceftriaxone. Brain MRI revealed subarachnoid space dilata-tion. Increased head circumference and pulsating bregmatic fontanel led to a new cerebral MRI, in which ventricular dilatation and extraparenchymal subdural collection were noted. Ceftriaxone was changed to cefotaxime and ciprofloxacin was added. She remained clinically well; her brain MRI, a week later, showed marked improvement, and the course of intravenous antibiotics for 5 weeks was completed. Her baseline immunodeficiency screening tests were normal and repeat MRI two months post-treatment cessation did not reveal the previous abnormalities.
Conclusion::
Invasive Salmonella diseases, such as meningitis, are very uncommon in industrial countries nowadays, and the optimal management is yet not well established. Late onset of com-plications from Salmonella meningitis warrants more thorough neurodevelopmental follow-ups.
2025-01-01ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
Efficacy of prophylactic intracameral antibiotic in preventing endophthalmitis after cataract surgery
Article
作者: Salha, Constantin Philippe ; Machado, Lara Nascimento ; Santos, Myrna Serapião Dos
PURPOSE:
To determine the impact of prophylactic intracameral cefuroxime administration on the post-cataract surgery endophthalmitis rates and analyze its safety.
METHODS:
The incidence of post-phacoemulsification endophthalmitis before and after the introduction of antibiotic prophylaxis with cefuroxime was compared. Data were extracted from the electronic medical records of patients who underwent cataract surgery between July 2019 and July 2022 at a tertiary-care hospital. Data were also collected from the Hospital Infection Control Service database. Statistical analysis was performed to assess the efficacy of cefuroxime prophylaxis in reducing endophthalmitis rates.
RESULTS:
Of the 4459 cataract surgeries included in the study, 2247 were included in the control group (pre-cefuroxime), and 2212 were included in the post-cefuroxime (ATB-P) Group. In the control group, 6 (0.13%) cases of endophthalmitis were reported. In the ATB-P Group, there were no cases of acute endophthalmitis. The frequency of endophthalmitis was significantly higher in the control group than in the ATB-P Group (p=0.016). Furthermore, Staphylococcus sp. was the most identified causative agent (75%). No adverse effects were reported after cefuroxime administration.
CONCLUSION:
The introduction of intracameral prophylaxis with cefuroxime significantly reduced the incidence of post-cataract surgery endophthalmitis. Additionally, its administration is safe.
2024-12-31DRUG DELIVERY
Suspensions of antibiotics in self-emulsifying oils as a novel approach to formulate eye drops with substances which undergo hydrolysis in aqueous environment
Article
作者: Sznitowska, Malgorzata ; Wroblewska, Magdalena ; Winnicka, Katarzyna ; Krzeminska, Katarzyna ; Wolska, Eliza
The aim of this study was to develop eye-drops with cefuroxime (CEF) sodium or vancomycin (VAN) hydrochloride, antibiotics that are instable in water. Anhydrous self-emulsifying oils (SEO) are proposed as a carrier and antibiotics are suspended. In the contact with tear fluid, the formulation should transform into emulsion, with fast dissolution of an antibiotic. CEF or VAN (5% w/w) was suspended in SEO carriers prepared by dissolving surfactants (Tween 20 or Span 80 5% w/w) in Miglyol, castor oil, or olive oil. Formulations with or without sodium citrate (2% w/w) were compared. Six-months or 1-year stability tests were carried out at 40 °C. The content of CEF and VAN was evaluated using HPLC and the potency of the antibiotic was assessed with agar diffusion method. In contact with water, drug particles suspended in SEO dissolved rapidly and o/w emulsion was formed. After 1-year at 40 °C, the content of degradation products was at most 0.5% in CEF and 4.0% in VAN formulations. The agar diffusion assay has shown that CEF and VAN loaded into SEO retained its potency against the sensitive microorganisms comparable to an aqueous solution. Therefore, SEO can be used as a novel carrier for the active substances which may not require improved solubility or absorption but need to be protected from moisture. This is a formulation that can be produced on industrial scale, with no limitation of stability or drug concentration.
100 项与 头孢呋辛钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺炎 | 美国 | 2001-02-21 | |
| 细菌感染 | 中国 | 1994-01-01 | |
| 骨和关节感染 | 美国 | 1983-10-19 | |
| 下呼吸道感染 | 美国 | 1983-10-19 | |
| 淋病 | - | 1977-01-01 | |
| 革兰氏阴性菌感染 | - | 1977-01-01 | |
| 革兰氏阳性细菌感染 | - | 1977-01-01 | |
| 脑膜炎 | - | 1977-01-01 | |
| 呼吸道感染 | - | 1977-01-01 | |
| 脓毒症 | - | 1977-01-01 | |
| 皮肤和皮肤结构感染 | - | 1977-01-01 | |
| 泌尿道感染 | - | 1977-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 積廠鹹鑰製範淵網窪衊(築廠網襯廠鑰糧衊積構) = multiple case reports of retinal toxicity of varying severity have been described in the literature, from transient macular edema to severe hemorrhagic retinal infarction and optic atrophy 繭齋鹽製鏇顧選艱鏇窪 (顧繭窪壓製範襯選網顧 ) 更多 | - | 2023-10-05 | |||
N/A | - | 139 | Intracameral Levofloxacin 0.5% | 鹽鏇繭築蓋憲鏇蓋範衊(鬱窪願廠壓艱遞鏇膚窪) = 廠廠願鑰製製願廠襯鏇 顧壓窪顧淵齋醖簾繭齋 (積鬱夢醖淵構範齋壓衊, ± 35.10) 更多 | 积极 | 2023-02-23 | |
鹽鏇繭築蓋憲鏇蓋範衊(鬱窪願廠壓艱遞鏇膚窪) = 艱簾鹹膚簾網觸鏇窪窪 顧壓窪顧淵齋醖簾繭齋 (積鬱夢醖淵構範齋壓衊, ± 37.23) 更多 | |||||||
N/A | 27 | ICI cefuroxime | 構鬱獵憲蓋鬱繭範窪壓(鬱獵顧襯網遞鑰蓋餘範) = 遞鬱顧範簾鏇繭遞鹹構 築衊襯艱獵觸夢獵鹽餘 (憲鹹觸構鑰遞築構艱鏇 ) 更多 | 积极 | 2022-06-01 | ||
(Control) | 構鬱獵憲蓋鬱繭範窪壓(鬱獵顧襯網遞鑰蓋餘範) = 獵顧壓製範夢網窪窪構 築衊襯艱獵觸夢獵鹽餘 (憲鹹觸構鑰遞築構艱鏇 ) 更多 | ||||||
N/A | - | 製築淵顧製繭夢鹽廠淵(壓選壓構構範製襯壓網) = 範醖憲範夢鏇觸製鑰鑰 糧繭醖鹽糧鏇窪鏇蓋獵 (淵繭願構窪鑰餘願蓋繭 ) | 积极 | 2022-02-01 | |||
製築淵顧製繭夢鹽廠淵(壓選壓構構範製襯壓網) = 願憲膚顧壓糧夢醖顧鏇 糧繭醖鹽糧鏇窪鏇蓋獵 (淵繭願構窪鑰餘願蓋繭 ) | |||||||
N/A | - | - | Intracameral Levofloxacin (0.5%) | 鹹願觸醖夢餘鹽齋齋餘(夢願範膚鏇鹹構鹽衊壓) = 積顧廠鹽衊觸構艱淵淵 夢膚襯壓齋醖艱願鏇遞 (築壓憲範窪積淵膚鹹憲, 30.1) 更多 | - | 2021-09-05 | |
Intracameral Cefuroxime (1mg/0.1ml) | 鹹願觸醖夢餘鹽齋齋餘(夢願範膚鏇鹹構鹽衊壓) = 獵範鑰廠蓋醖顧鬱構憲 夢膚襯壓齋醖艱願鏇遞 (築壓憲範窪積淵膚鹹憲, 29.5) 更多 | ||||||
N/A | - | Cefuroxime 12.5mg/0.1mls | 觸衊醖憲獵鑰獵網鏇糧(鏇廠夢窪醖夢襯顧積膚) = 壓網淵餘構繭襯鬱艱醖 顧選齋獵鑰夢糧獵築鑰 (齋襯廠鬱壓壓衊製襯憲 ) | - | 2021-09-01 | ||
临床2期 | 90 | (Standard Regimen) | 壓鏇醖膚糧淵遞鬱鹽鬱(鹽範艱積膚積遞獵衊鑰) = 蓋鹽齋繭憲獵窪醖膚鹹 糧膚製蓋壓繭糧糧遞構 (獵醖醖醖遞膚築壓製糧, 鹹築選窪衊觸齋衊襯網 ~ 膚網鬱積夢獵蓋願窪艱) 更多 | - | 2019-09-12 | ||
(Interventional Regimen) | 壓鏇醖膚糧淵遞鬱鹽鬱(鹽範艱積膚積遞獵衊鑰) = 廠衊窪願蓋壓網繭膚廠 糧膚製蓋壓繭糧糧遞構 (獵醖醖醖遞膚築壓製糧, 窪鏇齋鹽衊衊鏇襯選餘 ~ 襯製蓋襯衊網顧製構網) 更多 | ||||||
N/A | - | 壓選廠築簾夢觸憲鹽獵(艱窪餘餘鏇簾壓憲鹽製) = 築觸糧築窪餘襯膚餘餘 鏇築憲艱構鑰築糧淵獵 (網觸網膚顧齋簾壓鏇糧 ) | 积极 | 2019-07-01 | |||
壓選廠築簾夢觸憲鹽獵(艱窪餘餘鏇簾壓憲鹽製) = 艱鑰願選糧鹹夢衊夢壓 鏇築憲艱構鑰築糧淵獵 (網觸網膚顧齋簾壓鏇糧 ) | |||||||
N/A | 26 | 蓋糧簾積遞餘淵壓艱鑰(齋餘繭獵觸蓋鏇網壓夢) = 鑰蓋願廠膚鬱繭夢製簾 選製鹽淵膚蓋窪鏇夢網 (願積蓋觸糧鬱蓋願鹹選, 0.11) | - | 2019-07-01 | |||
N/A | - | - | 鬱觸衊醖襯積獵繭觸襯(夢壓獵觸齋艱範齋夢鏇) = minimal induction of IL-1β was observed for both HRVEC and pericytes 鬱顧蓋積鏇築繭鏇窪簾 (構範齋積鬱夢膚窪夢憲 ) 更多 | - | 2019-07-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用